|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.
|
31782267 |
2020 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Paired analysis of tumour-derived versus blood-derived DNA to determine the prevalence of deleterious somatic variants in OC predisposition genes (<i>ATM</i>, <i>BRCA1/2, BRIP1</i>, <i>MSH2/6</i>, <i>PALB2</i>, <i>RAD51C/D</i> and <i>TP53</i>) and the <i>PIK3CA</i> and <i>PTEN</i> genes in individuals with OC (AGO-TR1 study, NCT02222883).
|
30979843 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function variants in RAD51C are associated with familial ovarian cancer, but its role in hereditary breast cancer remains unclear.
|
30949688 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The analysis also showed a substantial difference in the profile of genes contributing to either BC or OC risk, including genes specifically associated with a high risk of OC but not BC (e.g., RAD51C, and RAD51D).
|
30733081 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
|
29233532 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% of BC and 3.2%/4.88% of OC in UK/US women: 657/655 OC cases and 2420/2386 BC cases prevented per million.
|
29361001 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
The rare finding of a clearly truncating RAD51C mutation in an early-onset BC patient with a BC-only family history supports the notion that compromised RAD51C function may result in both BC and OC.
|
27622768 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Despite a high prevalence of deleterious missense variants, most studies of RAD51C ovarian cancer susceptibility gene only provide in silico pathogenicity predictions of missense changes.
|
28829762 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The results of pedigree analysis showed that the proband with a large deletion on RAD51C had a family history of both breast and ovarian cancer, and the families of probands with novel BRIP1 missense variants included a male patient with breast cancer or many patients with breast cancer within the second-degree relatives.
|
28796317 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall, pathogenic RAD51C mutations were identified in 0.5 % of Danish families with increased risk of hereditary breast and/or ovarian cancer.
|
26740214 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We evaluated 11 genes associated with ovarian carcinoma (BARD1, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51D, and RAD51C) and additional candidate genes in DNA repair (ATM, BAP1, CHEK2, MRE11A, NBN, PTEN, TP53).
|
26718727 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
RAD51C has been identified as a potential tumor suppressor and a breast and ovarian cancer susceptibility gene.
|
27753535 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
These results confirm that RAD51C and RAD51D are moderate ovarian cancer susceptibility genes and suggest that they confer levels of risk of EOC that may warrant their use alongside BRCA1 and BRCA2 in routine clinical genetic testing.
|
26261251 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
RAD51C is primarily an ovarian cancer susceptibility gene.
|
25470109 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients.
|
26057125 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
The RAD51 paralog RAD51C has been identified as a breast and ovarian cancer susceptibility gene.
|
25292178 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2, and RAD51C in a large well-annotated patient set.
|
24504028 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Deleterious and missense mutations of RAD51C have recently been suggested to modulate the individual susceptibility to hereditary breast and ovarian cancer and unselected ovarian cancer, but not unselected breast cancer (BrC).
|
25343521 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our results support that RAD51C is a rare breast and ovarian cancer susceptibility gene and may contribute to a small fraction of families including breast and ovarian cancer cases and families with only breast cancer.
|
25086635 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Biallelic RAD51C mutations cause Fanconi anemia, and monoallelic mutations predispose women to breast and ovarian cancer.
|
24800917 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
There is ongoing debate whether pathogenic RAD51C alterations increase the relative risk for BC in addition to that for OC, which was estimated to be 5.88 (95% confidence interval = 2.91 to 11.88; P = 7.65 × 10(-7)).
|
24359560 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Germline RAD51C mutations in ovarian cancer susceptibility.
|
22725699 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Deleterious mutations in the RAD51C gene, which encodes a DNA double-strand break repair protein, have been reported to confer high-penetrance susceptibility to both breast and ovarian cancer.
|
22476429 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
Biomarker
|
disease |
BEFREE |
An increased cancer risk has been firmly established for carriers of mutations in FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, RAD51C/FANCO and link the FA pathway to inherited breast and ovarian cancer.
|
22829014 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not breast cancer in the absence of ovarian cancer.
|
23176254 |
2012 |